To the Editor.—

The recent paper by Levaux et al that compares a 2-dose hepatitis vaccination regimen against a 3-dose regimen makes some quantitative errors or assumptions that bias results in favor of the 2-dose hepatitis B regimen. First, the authors assume vaccine seroprotection rates for completion of the 2- and 3-dose regimens are 99.2% and 98.3%, respectively. The sole study on which these rates are based indicates this difference has a P value of .62. In fact, had one fewer person in the 2-dose arm seroconverted, the observed seroprotection rates would be both mathematically and statistically equivalent. It would have been more prudent to use the weighted average of the 2 seroprotection rates for both regimens when building economic models. Second, the authors presume that the probability of receiving the second dose among those receiving the first dose is equivalent in both the 2-dose and 3-dose...

You do not currently have access to this content.